These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Primary augmentation pharyngoplasty with calcium hydroxylapatite for treatment of velopharyngeal insufficiency: Surgical and speech outcomes.
    Author: Munson PD, Ward A.
    Journal: Int J Pediatr Otorhinolaryngol; 2018 May; 108():91-94. PubMed ID: 29605374.
    Abstract:
    INTRODUCTION: Augmentation pharyngoplasty (AP) is a technique that may effectively treat velopharyngeal insufficiency (VPI), while avoiding typical short and long term surgical risks. This study seeks to determine if children with VPI treated by AP with calcium hydoxylapatite (CaHa) demonstrate clinically significant improvement in speech outcomes. METHODS: Retrospective review (2012-2016) of prospectively collected database of children with VPI, cared for at a single tertiary children's hospital. Preoperative speech assessment, nasometry, and video nasendoscopy were used to identify patients with VPI treated by AP with CaHa. Demographics, surgical/speech outcomes, complications, novel surgical technique and follow-up were recorded. Main outcome measures included pre and postoperative nasality and perceptual speech assessments, based on the Pittsburgh Weighted Values for Speech (PWS). RESULTS: 17 patients treated with AP with CaHa, as initial primary treatment for VPI, were identified. 8 patients had cleft palate, 9 patients had isolated VPI. Mean age at treatment was 6.6 years, with no operative complications. Mean nasality scores before and after surgery were 3.2 vs. 0.5 (p < 0.001). Mean PWS before and after surgery were 9.7 vs. 2.1 (p < 0.001). Based on the PWS scoring, 4/8 of cleft patients (50%) and 8/9 of isolated patients (89%) achieved a competent/borderline competent nasopharyngeal valve. 17/17 of patients (100%) had improvement in nasality. Mean length of follow-up was 32.8 months (range 10-64 months). CONCLUSION: In this largest series of patients to date, AP with CaHa is a safe, minimally invasive, enduring treatment for VPI in properly selected patients. Nasality and speech scores significantly improved, especially in patients with isolated VPI.
    [Abstract] [Full Text] [Related] [New Search]